title: [Clinical pilot study on the rhinitis due to laryngopharyngeal reflux].
abstract: OBJECTIVE
  To explore the relevance between nasal symptoms and laryngopharyngeal reflux disease in patients with allergic rhinitis.
  
  
  METHODS
  Thirty patients of laryngopharyngeal reflux disease were diagnosed in ENT outpatient department in our hospital. All patients have symptoms of sneeze, nasal discharge as chief complaint and they responded no effect for other normal treatment for nasal-sinusitis at least three months. Orally before meals, a dose of 5 mg Mosapride citrate each time, three times a day for 7 days. Orally before meals, a dose of 20 mg Esomeprazole each time, two times a. day for 2-3 months. Nasal spray, one spray of azelastine hydrochloride once, two times a day for 2 month.
  
  
  RESULTS
  Laryngopharyngeal reflux symptom scores at four time points (the first visit, post treatment 15 days, 45 days, 75 days) were analyzed by repeated measures analysis of variance. There is a significant difference in four time points.
  
  
  CONCLUSIONS
  Laryngopharyngeal reflux disease has a strong association with allergic rhinitis. Patients who has allergic rhinitis nasal symptoms as chief complaint must be exclude, the laryngopharyngeal reflux disease first.
authors.forename: Yanqiao
authors.initials: Y
authors.lastname: Wu
authors.forename: Fangfang
authors.initials: F
authors.lastname: Liang
mesh_terms: D001549:Benzamides / Q000627:therapeutic use; D064098:Esomeprazole / Q000627:therapeutic use; D006801:Humans; D057045:Laryngopharyngeal Reflux / Q000150:complications* / Q000188:drug therapy; D009025:Morpholines / Q000627:therapeutic use; D010793:Phthalazines / Q000627:therapeutic use; D010865:Pilot Projects; D065631:Rhinitis, Allergic / Q000188:drug therapy / Q000209:etiology*
chemical_list: D001549:Benzamides; D009025:Morpholines; D010793:Phthalazines; C062720:mosapride; D064098:Esomeprazole; C020976:azelastine